Tazverik

Chemical Nametazemetostat
Dosage FormTablet (oral; 200 mg)
Drug ClassInhibitors
SystemMusculoskeletal, Skin
CompanyEpizyme
Approval Year2020

Indication

  • For the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection
Last updated on 3/24/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tazverik (tazemetostat) Prescribing Information.2020Epizyme Inc., Cambridge, MA